Higher force sensitivity (Subcategory of GEARS Score) and Total GEARS Score correlated with lower nerve forces applied with total energy (J) -0.66(0.019) and -0.87(0.000), respectively. VUA leak rate was correlated with RACE score -0.86 (0.000), which was significantly different between novices and experts (p[0.003).
INTRODUCTION AND OBJECTIVES: High-intensity focused ultrasound (HIFU) can be used to ablate prostate cancer (CaP) focally, noninvasively, and with minimal side effects. In this video, we present a method for focal HIFU, employing (1) multiparametric magnetic resonance imaging (mpMRI), (2) fusion biopsy, (3) margin generation, and (4) treatment.
METHODS: After mpMRI is performed, prostate regions suspicious for CaP (PIRADSv2) are identified and contoured by an experienced radiologist. Suspicious regions receive targeted biopsy with an MRI-ultrasound fusion system; 10-12 systematic cores are also obtained. Patients are potentially eligible for focal HIFU if they harbor a single focus of organ-confined, clinically significant disease with Gleason Score (GS) 4þ3 and prostate volume 55 CC.
To generate a treatment margin, the original MR target is expanded 1 to 2 cm; prior studies informed our use of asymmetrical margins that were largest along the base-apex axis (Priester, J.Urol. 2016). Next, the biopsy coordinates are imported, and the margin is refined by excluding CaPnegative cores with ! 1 cm of tissue. Lastly, anatomic regions can be excluded from treatment. The urethra is spared whenever possible, with the risk of side effects weighed against the possibility of positive margins.
The plan (Fig 1) is visualized and reviewed using open source software (3D Slicer). All surfaces (prostate, MR target, biopsy cores, margin, and urethra) are then exported to the HIFU device and overlaid on real-time ultrasound. Patients receive follow-up mpMRI and biopsy at 6 months.
RESULTS: To date, this method has been used for focal HIFU in 20 patients. Plan generation is semi-automated and takes about 30 minutes. On average, 9.4 CC (29% of prostate tissue) was treated using these margins, with reduced treatment time relative to hemi-or whole-gland HIFU. Of 7 patients with 6-month follow-up biopsy, none had residual pattern 4 disease, but 3 of 7 had small-volume GS [ 3þ3.
CONCLUSIONS: Treatment margins can be created in a patient-specific manner, incorporating data from MRI, fusion biopsy, and prostate anatomy. This approach helps to ensure cancer control while minimizing procedure time and damage to healthy tissue.
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V08-08 A NOVEL CASE COMBINING PSMA BASED (18)F-DCFPYL PET/CT AND MRI/ULTRASOUND FUSION GUIDED BIOPSY TO ASSESS LOCAL RECURRENCE OF PROSTATE CANCER
Gustavo Pena*, Shawn Marhamati, Peter Pinto, Baris Turkbey, Bradford Wood, Sandeep Gurram, Peter Choyke, Bethesda, MD INTRODUCTION AND OBJECTIVES: 11-31% of radical prostatectomies (RP) are associated with positive surgical margins (PSM) depending on approach and pre-operative risk.
[1] Differentiating residual normal tissue from persistent or recurrent cancer in the setting of biochemical recurrence can be challenging. Modern MRI studies have reported 94% sensitivity and 100% specificity for detecting local recurrence in lesions 7.6mm or greater in length.
[2] If the tissue in question is detected on MRI, MRI/ultrasound fusion biopsy (fusion biopsy) of these lesions have demonstrated per patient cancer detection rates of 80%. [3] PSMA based F:18 PET CT has shown promise at detecting recurrence, with optimal cut-off PSA value to predict a positive 18F-DCFBC scan reported to be as low as 0.78 ng/mg. [4] The combination of these modalities can be used to more accurately differentiate benign tissue from residual or recurrent disease.
METHODS: We present a case of a patient enrolled on National Institutes of Health (NIH) protocol 2017-C-0109, (18)F-DCFPyL PET/CT (DCFPyL) in High Risk and Recurrent Prostate Cancer. This 73M underwent RP with PSM with invasive carcinoma at margins. Postoperative PSA was detectable. He was initially treated with salvage radiation and later referred to the NIH for continued PSA rise. Metastatic workup with conventional imaging was negative. Between July-September 2018, he underwent MRI prostate, DCFPyL, and fusion biopsy. RESULTS: MRI: 2.6 cm lesion at inferior-mid portion of the prostatectomy bed. Score: Likely residual normal prostate tissue. 0.8 cm tissue lesion at 2 o'clock direction at mid-prostatectomy bed. Score: Low-moderate.1.6 cm lesion right superior portion of the prostatectomy bed. Score: Moderate. Seminal vesicles (SV) present bilaterally with a subtle focus at DCE MRI in the right seminal vesicles. No bony or nodal disease.
